Assessment of the prognostic impact of additional cytogenetic abnormalities at diagnosis in a cohort of chronic myeloid leukemia patients

• Grant number: 23/17871-6
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Start date: April 01, 2024
• End date: March 31, 2025
• Field of knowledge: Health Sciences - Medicine
• Principal Investigator: Katia Borgia Barbosa Pagnano
• Grantee: Gustavo Emmanuel Alves Abrantes Santos
• Host Institution: Centro de Hematologia e Hemoterapia (HEMOCENTRO). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm that accounts for approximately 15% of all leukemia cases diagnosed in adults. While in the past the mortality rate was 10-20%, today it reaches around 1-2%. The disease is characterized by the presence of the Philadelphia chromosome, which is the result of a reciprocal translocation between the long arms of chromosomes 9 (ch9) and 22 (ch22), resulting in the chimeric oncogene BCR:ABL1, which encodes a protein with homologous tyrosine kinase activity. Diagnosis is confirmed by the presence of leukocytosis in the blood count, karyotype with t(9;22) and molecular tests that demonstrate the presence of BCR::ABL1. The disease is treated with tyrosine kinase inhibitors. Patients treated in the Unified Health System (SUS) are treated with imatinib mesylate as first-line therapy, with generic formulations being used since 2013. Additional chromosomal abnormalities (ACAs) present at diagnosis may influence the course of the disease. The present study aims primarily to evaluate overall survival in patients with CML treated with imatinib according to the type of ACA at diagnosis. Secondary objectives are to evaluate event-free survival and progression-free survival. Clinical and laboratory data from a cohort of patients with CML treated with generic imatinib between January 2015 and December 2018 will be evaluated.